Cerus (NASDAQ:CERS – Get Rating) and Longview Acquisition Corp. II (NYSE:LGV – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Volatility & Risk
Cerus has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Longview Acquisition Corp. II has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for Cerus and Longview Acquisition Corp. II, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Longview Acquisition Corp. II||0||0||0||0||N/A|
This table compares Cerus and Longview Acquisition Corp. II’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Longview Acquisition Corp. II||N/A||-65.52%||3.65%|
Insider & Institutional Ownership
82.5% of Cerus shares are held by institutional investors. Comparatively, 66.3% of Longview Acquisition Corp. II shares are held by institutional investors. 7.3% of Cerus shares are held by insiders. Comparatively, 26.4% of Longview Acquisition Corp. II shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Cerus and Longview Acquisition Corp. II’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cerus||$157.88 million||3.65||-$54.38 million||($0.22)||-14.77|
|Longview Acquisition Corp. II||N/A||N/A||$7.40 million||N/A||N/A|
Longview Acquisition Corp. II has lower revenue, but higher earnings than Cerus.
Cerus beats Longview Acquisition Corp. II on 6 of the 10 factors compared between the two stocks.
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
About Longview Acquisition Corp. II
Longview Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on businesses in the healthcare, industrials, consumer, media, technology, and technology services sector. The company was incorporated in 2020 and is based in New York, New York.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.